Paths forward for bringing ZMCs to the clinic include directing their action more specifically to cancer cells by offloading their ROS generation to CR or employing cancer cell-targeted delivery systems, and to leverage the cell’s own zinc homeostasis mechanisms to transiently elevate intracellular zinc long enough for mutant p53 to begin its transcriptional programming. Here, TP53 is linked to cancer.